Key Points
-
Retinoids and rexinoids exert their action by signalling through nuclear receptor heterodimers that can activate or silence specific gene networks.
-
The most widely studied retinoid, all-trans retinoic acid (ATRA), causes differentiation of acute promyelocytic leukaemia (APL) cells through activation of the retinoid receptor RARα, but RARβ and rexinoid receptors (RXRs) might also be responsible for some of the antitumour activity of retinoids.
-
Crosstalk with other transcription factors, particularly AP1 (FOS–JUN), might account for some of the antitumour activity of retinoids.
-
In humans, pharmacological doses of ATRA cause differentiation of APL cells that contain the PML–RARα fusion protein, but clinical data indicate that retinoids might also be useful for the treatment of other human cancers.
-
As well as activating differentiation, retinoids can also activate tumour-specific death signalling pathways; these contribute to the efficacy of retinoid therapy.
-
Retinoids are cancer preventive and their use has been approved for the treatment of several precancerous conditions.
Abstract
Retinoids have a reputation for being both detrimental and beneficial: they are teratogens, but they also have tumour-suppressive capacity. Cell biology and genetics have significantly improved our understanding of the mechanisms that underlie the anti-proliferative action of retinoids. Recent elucidation of the pathways that are activated by retinoids will help us to exploit the beneficial aspects of this powerful class of compounds for cancer therapy and prevention.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Niederreither, K., Subbarayan, V., Dolle, P. & Chambon, P. Embryonic retinoic acid synthesis is essential for early mouse post-implantation development. Nature Genet. 21, 444–448 (1999).Targeted gene disruption shows that production of retinoic acid by the retinaldehyde dehydrogenase-2 (Raldh2) enzyme is required for mouse embryo survival and early morphogenesis.
de Urquiza, A. M. et al. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 290, 2140–2144 (2000).Identification of brain-derived docosahexaenoic acid as an RXR ligand.
Krezel, W. et al. Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. Science 279, 863–867 (1998).
Kastner, P. et al. Abnormal spermatogenesis in RXRβ mutant mice. Genes Dev. 10, 80–92 (1996).
Massaro, G. D. et al. Retinoic acid receptor-β: an endogenous inhibitor of the perinatal formation of pulmonary alveoli. Physiol. Genomics 4, 51–57 (2000).
Wan, Y. J. et al. Hepatocyte-specific mutation establishes retinoid X receptor-α as a heterodimeric integrator of multiple physiological processes in the liver. Mol. Cell Biol. 20, 4436–4444 (2000).
Imai, T., Jiang, M., Kastner, P., Chambon, P. & Metzger, D. Selective ablation of retinoid X receptor-α in hepatocytes impairs their lifespan and regenerative capacity. Proc. Natl Acad. Sci. USA 98, 4581–4586 (2001).
Dupe, V. et al. Essential roles of retinoic acid signaling in interdigital apoptosis and control of BMP-7 expression in mouse autopods. Dev. Biol. 208, 30–43 (1999).
Altucci, L. et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand trail. Nature Med. 7, 680–686 (2001).Retinoic-acid therapy of acute promyelocytic leukaemia involves induction of cell differentiation linked to early-induced anti-apoptotic gene programming, which is followed by post-differentiation apoptosis caused by activation of the TRAIL signalling pathway.
Kastner, P. et al. Genetic evidence that the retinoid signal is transduced by heterodimeric RXR/RAR functional units during mouse development. Development 124, 313–326 (1997).
Chen, J. Y. et al. RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J. 14, 1187–1197 (1995).
Arnhold, T., Tzimas, G., Wittfoht, W., Plonait, S. & Nau, H. Identification of 9-cis-retinoic acid, 9,13-di-cis-retinoic acid, and 14-hydroxy-4,14-retro-retinol in human plasma after liver consumption. Life Sci. 59, L169–L177 (1996).
Buck, J., Derguini, F., Levi, E., Nakanishi, K. & Hammerling, U. Intracellular signaling by 14-hydroxy-4,14-retro-retinol. Science 254, 1654–1656 (1991).
Bourguet, W. et al. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol. Cell 5, 289–298 (2000).
Jepsen, K. et al. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 102, 753–763 (2000).
Bourguet, W., Germain, P. & Gronemeyer, H. Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol. Sci. 21, 381–388 (2000).
Glass, C. K. & Rosenfeld, M. G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14, 121–141 (2000).
Rachez, C. & Freedman, L. P. Mediator complexes and transcription. Curr. Opin. Cell Biol. 13, 274–280 (2001).
Ito, M. & Roeder, R. G. The TRAP/SMCC/mediator complex and thyroid hormone receptor function. Trends Endocrinol. Metab. 12, 127–134 (2001).
Benoit, G. et al. RAR-independent RXR signaling induces t(15;17) leukemia cell maturation. EMBO J. 18, 7011–7018 (1999).
Benoit, G. R. et al. Autonomous rexinoid death signaling is suppressed by converging signaling pathways in immature leukemia cells. Mol. Endocrinol. 15, 1154–1169 (2001).Together with reference 20 , this is the first demonstration of autonomous rexinoid signalling.
Kastner, P., Mark, M. & Chambon, P. Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Cell 83, 859–869 (1995).
Pasqualetti, M., Neun, R., Davenne, M. & Rijli, F. M. Retinoic acid rescues inner ear defects in Hoxa1 deficient mice. Nature Genet. 29, 34–39 (2001).
Fisher, G. J. & Voorhees, J. J. Molecular mechanisms of retinoid actions in skin. FASEB J. 10, 1002–1013 (1996).
Massaro, G. D. & Massaro, D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nature Med. 3, 675–677 (1997).
Gerster, H. Vitamin A: functions, dietary requirements and safety in humans. Int. J. Vitam. Nutr. Res. 67, 71–90 (1997).
Corcoran, J. & Maden, M. Nerve growth factor acts via retinoic acid synthesis to stimulate neurite outgrowth. Nature Neurosci. 2, 307–308 (1999).
Mollard, R., Ghyselinck, N. B., Wendling, O., Chambon, P. & Mark, M. Stage-dependent responses of the developing lung to retinoic acid signaling. Int. J. Dev. Biol. 44, 457–462 (2000).
Widschwendter, M. et al. Methylation and silencing of the retinoic acid receptor-β2 gene in breast cancer. J. Natl Cancer Inst. 92, 826–832 (2000).Studies in breast cancer cell lines and patient biopsies indicate that methylation of the RARβ2 gene might be an initial step in breast carcinogenesis. This study indicates that treatment with demethylating agents followed by retinoic acid might offer a new therapeutic modality.
Bovenzi, V. & Momparler, R. L. Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor-β and estrogen receptor-α genes in breast carcinoma cells. Cancer Chemother. Pharmacol. 48, 71–76 (2001).
Lin, B. et al. Orphan receptor COUP-TF is required for induction of retinoic acid receptor-β, growth inhibition, and apoptosis by retinoic acid in cancer cells. Mol. Cell Biol. 20, 957–970 (2000).
Wong, C. W. & Privalsky, M. L. Transcriptional silencing is defined by isoform- and heterodimer-specific interactions between nuclear hormone receptors and corepressors. Mol. Cell Biol. 18, 5724–5733 (1998).
Germain, P., Iyer, J., Zechel, C. & Gronemeyer, H. Coregulator recruitment and the mechanism of retinoic acid receptor synergy. Nature (in the press).
Lin, F., Xiao, D., Kolluri, S. K. & Zhang, X. Unique anti-activator protein-1 activity of retinoic acid receptor-β. Cancer Res. 60, 3271–3280 (2000).
Dong, Z., Birrer, M. J., Watts, R. G., Matrisian, L. M. & Colburn, N. H. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc. Natl Acad. Sci. USA 91, 609–613 (1994).Retinoic acid inhibits TPA-induced transformation and anchorage-independent cell growth in the dose range that blocks TPA-induced AP-1 activity, indicating (as in reference 11 ) that its prevention of tumour promotion might occur through inhibition of AP1 activity.
Greenhalgh, D. A., Welty, D. J., Player, A. & Yuspa, S. H. Two oncogenes, v-fos and v-ras, cooperate to convert normal keratinocytes to squamous cell carcinoma. Proc. Natl Acad. Sci. USA 87, 643–647 (1990).
Leder, A., Kuo, A., Cardiff, R. D., Sinn, E. & Leder, P. v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. Proc. Natl Acad. Sci. USA 87, 9178–9182 (1990).A transgenic mouse strain carrying the activated v- HRAS oncogene developed papillomas, some of which went on to develop squamous-cell carcinomas and, more frequently, sarcomas, following treatment with the tumour promoter TPA. Retinoic acid markedly delayed, reduced and often completely inhibited the appearance of TPA-induced papillomas.
Göttlicher, M., Heck, S. & Herrlich, P. Transcriptional cross-talk, the second mode of steroid hormone receptor action. J. Mol. Med. 76, 480–489 (1998).
Resche-Rigon, M. & Gronemeyer, H. Therapeutic potential of selective modulators of nuclear receptor action. Curr. Opin. Chem. Biol. 2, 501–507 (1998).
Fanjul, A. et al. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 372, 107–111 (1994).
Chen, J. Y. et al. Two distinct actions of retinoid-receptor ligands. Nature 382, 819–822 (1996).
Nagy, L. et al. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol. Cell Biol. 15, 3540–3551 (1995).Original demonstration that RXR activity is required to induce apoptosis in this cell system.
Li, M. et al. Skin abnormalities generated by temporally controlled RXRα mutations in mouse epidermis. Nature 407, 633–636 (2000).
Sun, S. Y. et al. Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin. Cancer Res. 6, 1563–1573 (2000).
Gottardis, M. M. et al. Chemoprevention of mammary carcinoma by lGD1069 (targretin): An RXR-selective ligand. Cancer Res. 56, 5566–5570 (1996).A 90% reduction in tumour burden and tumour incidence by rexinoid treatment in a methylnitrosurea-induced rat mammary carcinoma model. Chronic rexinoid therapy showed no signs of 'retinoid-associated' toxicities.
Agarwal, V. R., Bischoff, E. D., Hermann, T. & Lamph, W. W. Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand lGD1069 (targretin). Cancer Res. 60, 6033–6038 (2000).
Gamage, S. D. et al. Efficacy of lGD1069 (targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma. J. Pharmacol. Exp. Ther. 295, 677–681 (2000).
Miller, V. A. et al. Initial clinical trial of a selective retinoid X receptor ligand, lGD1069. J. Clin. Oncol. 15, 790–795 (1997).
Holmes, W. F., Dawson, M. I., Soprano, R. D. & Soprano, K. J. Induction of apoptosis in ovarian carcinoma cells by AHPN/CD437 is mediated by retinoic acid receptors. J. Cell Physiol. 185, 61–67 (2000).
Sun, S. Y., Yue, P., Hong, W. K. & Lotan, R. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (trail)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)- 4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of trail receptors in human lung cancer cells. Cancer Res. 60, 7149–7155 (2000).TRAIL receptor upregulation by an atypical retinoid.
Sun, S. Y., Yue, P., Hong, W. K. & Lotan, R. Induction of FAS expression and augmentation of FAS/FAS ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res. 60, 6537–6543 (2000).
Dawson, M. I. et al. Apoptosis induction in cancer cells by a novel analogue of 6-[3-(1- adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid lacking retinoid receptor transcriptional activation activity. Cancer Res. 61, 4723–4730 (2001).
Li, H. et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 289, 1159–1164 (2000).
Sakaue, M., Adachi, H., Dawson, M. & Jetten, A. M. Induction of EGR-1 expression by the retinoid AHPN in human lung carcinoma cells is dependent on activated ERK1/2. Cell Death Differ. 8, 411–424 (2001).
Chen, Y., Buck, J. & Derguini, F. Anhydroretinol induces oxidative stress and cell death. Cancer Res. 59, 3985–3990 (1999).
Pandolfi, P. P. Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia. Hum. Mol. Genet. 10, 769–775 (2001).
He, L. Z. et al. Distinct interactions of PML–RARα and PLZF–RARα with co-repressors determine differential responses to RA in APL. Nature Genet. 18, 126–135 (1998).
Lin, R. J. et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391, 811–814 (1998).
Grignani, F. et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature 391, 815–818 (1998).References 57–59 show that aberrant corepressor interaction of the APL oncofusion proteins leads to stabilization of the HDAC complex and, therefore, enhanced silencing of target genes. Retinoic acid can dissociate the HDAC complex from PML–RARα but not PLZF–RARα, as the latter contains an additional corepressor-binding surface.
Minucci, S. et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol. Cell 5, 811–820 (2000).
Perez, A. et al. PML–RAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. EMBO J. 12, 3171–3182 (1993).
Lin, R. J. & Evans, R. M. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol. Cell 5, 821–830 (2000).References 60–62 show that oligomerization of PML–RARα accounts for its aberrant recruitment of HDAC-containing corepressor complexes.
Guo, A. et al. The function of PML in p53-dependent apoptosis. Nature Cell Biol. 2, 730–736 (2000).
Pearson, M. et al. PML regulates p53 acetylation and premature senescence induced by oncogenic RAS. Nature 406, 207–210 (2000).
Zhong, S. et al. Role of SUMO-1-modified PML in nuclear body formation. Blood 95, 2748–2752 (2000).
Zhong, S., Salomoni, P. & Pandolfi, P. P. The transcriptional role of PML and the nuclear body. Nature Cell Biol. 2, E85–E90 (2000).
Khan, M. M. et al. Role of PML and PML–RARα in MAD-mediated transcriptional repression. Mol. Cell 7, 1233–1243 (2001).
Cheng, G. X. et al. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF–RARα and NPM–RARα. Proc. Natl Acad. Sci. USA 96, 6318–6323 (1999).
Lallemand-Breitenbach, V. et al. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor-α degradation. J. Exp. Med. 193, 1361–1372 (2001).
French, L. E. & Tschopp, J. The trail to selective tumor death. Nature Med. 5, 146–147 (1999).
Fenaux, P., Chomienne, C. & Degos, L. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin. Hematol. 38, 13–25 (2001).
Zelent, A. Hot on the trail of acute promyelocytic leukemia. Nature Med. 7, 662–664 (2001).
Bonavida, B., Ng, C. P., Jazirehi, A., Schiller, G. & Mizutani, Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics. Int. J. Oncol. 15, 793–802 (1999).
Marks, P. A., Richon, V. M. & Rifkind, R. A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl Cancer Inst. 92, 1210–1216 (2000).
Warrell, R. P. Jr, He, L. Z., Richon, V., Calleja, E. & Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl Cancer Inst. 90, 1621–1625 (1998).First report of complete clinical and cytogenetic remission of a relapsed APL patient by treatment with all- trans -retinoic acid in combination with the HDAC inhibitor sodium phenylbutyrate.
Novogrodsky, A. et al. Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer 51, 9–14 (1983).
Minucci, S., Nervi, C., Lo Coco, F. & Pelicci, P. G. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20, 3110–3115 (2001).
Ferrara, F. F. et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 61, 2–7 (2001).Restoration of retinoic acid-induced differentiation in non-APL AML blasts by co-treatment with an HDAC inhibitor.
Cote, S. et al. Altered ligand binding and transcriptional regulation by mutations in the PML/RARα ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia. Blood 96, 3200–3208 (2000).
Hong, W. K. & Itri, L. M. in The Retinoids: Biology, Chemistry and Medicine (eds Sporn, M. B., Roberts, A. B. & Goodman, D. S.) 597–658 (Raven, New York, 1994).
Moon, R. C., Mehta, R. G. & Rao, K. J. V. N. in The Retinoids (eds Sporn, M. B., Roberts, A. B. & Goodman, D. S.) 573–595 (Raven, New York, 1994).
Gong, B. & Almasan, A. Genomic organization and transcriptional regulation of human APO2/TRAIL gene. Biochem. Biophys. Res. Commun. 278, 747–752 (2000).
Ma, X. et al. Regulation of interferon and retinoic acid-induced cell death activation through thioredoxin reductase. J. Biol. Chem. 276, 24843–24854 (2001).
List, H. J. et al. Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J. Biol. Chem. 276, 23763–23768 (2001).
Bubulya, A., Wise, S. C., Shen, X. Q., Burmeister, L. A. & Shemshedini, L. c-JUN can mediate androgen receptor-induced transactivation. J. Biol. Chem. 271, 24583–24589 (1996).
Pearce, D., Matsui, W., Miner, J. N. & Yamamoto, K. R. Glucocorticoid receptor transcriptional activity determined by spacing of receptor and nonreceptor DNA sites. J. Biol. Chem. 273, 30081–30085 (1998).
Kamei, Y. et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85, 403–414 (1996).
Caelles, C., Gonzalez-Sancho, J. M. & Munoz, A. Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev. 11, 3351–3364 (1997).
Rogatsky, I., Logan, S. K. & Garabedian, M. J. Antagonism of glucocorticoid receptor transcriptional activation by the c-JUN N-terminal kinase. Proc. Natl Acad. Sci. USA 95, 2050–2055 (1998).
Zhou, X. F., Shen, X. Q. & Shemshedini, L. Ligand-activated retinoic acid receptor inhibits AP-1 transactivation by disrupting c-JUN/c-FOS dimerization. Mol. Endocrinol. 13, 276–285 (1999).
Mann, K. K., Shao, W. & Miller, W. H. Jr. The biology of acute promyelocytic leukemia. Curr. Oncol. Rep. 3, 209–216 (2001).
Branchet, M. C. et al. Topical tretinoin in the treatment of lichen planus and leukoplakia of the oral mucosa. A biochemical evaluation of the keratinization. Ann. Dermatol. Venereol. 121, 464–469 (1994).
Boisnic, S. et al. Topical tretinoin in the treatment of lichen planus and leukoplakia of the mouth mucosa. A clinical evaluation. Ann. Dermatol. Venereol. 121, 459–463 (1994).
Peck, G. L. Topical tretinoin in actinic keratosis and basal cell carcinoma. J. Am. Acad. Dermatol. 15, 829–835 (1986).
Meyskens, F. L. Jr, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J. Natl Cancer Inst. 86, 539–543 (1994).
Schmutzler, C. & Kohrle, J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 10, 393–406 (2000).
Grunwald, F. et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J. Nucl. Med. 39, 1903–1906 (1998).
Grunwald, F. et al. Redifferentiation therapy with retinoic acid in follicular thyroid cancer. J. Nucl. Med. 39, 1555–1558 (1998).
Kelly, W. K. et al. The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer. Clin. Cancer Res. 6, 838–846 (2000).
Dezube, B. J. AIDS-related Kaposi sarcoma: the role of local therapy for a systemic disease. Arch. Dermatol. 136, 1554–1556 (2000).
Duvic, M. et al. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase I and II trials. Arch. Dermatol. 136, 1461–1469 (2000).
Mitsuyasu, R. T. AIDS-related Kaposi's sarcoma: current treatment options, future trends. Oncology 14, 867–878 (2000).
Von Roenn, J. H. & Cianfrocca, M. Treatment of Kaposi's sarcoma. Cancer Treat. Res. 104, 127–148 (2001).
Somos, S. & Farkas, B. Immunomodulatory treatment with low-dose interferon-α and oral retinoic acid in lymphangioma-like Kaposi's sarcoma. Anticancer Res. 20, 541–545 (2000).
Lawrence, J. A. et al. Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations. J. Clin. Oncol. 19, 2754–2763 (2001).
Miller, W. H. Jr, et al. A phase I–II study of 9-cis retinoic acid and interferon-α2b in patients with advanced renal-cell carcinoma: an NCIC clinical trials group study. Ann. Oncol. 11, 1387–1389 (2000).
Motzer, R. J. et al. Phase III trial of interferon α-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J. Clin. Oncol. 18, 2972–2980 (2000).
Kurie, J. M. et al. Phase I trial of 9-cis retinoic acid in adults with solid tumors. Clin. Cancer Res. 2, 287–293 (1996).
DiGiovanna, J. J. Retinoid chemoprevention in patients at high risk for skin cancer. Med. Pediatr. Oncol. 36, 564–567 (2001).
DiGiovanna, J. J. Systemic retinoid therapy. Dermatol. Clin. 19, 161–167 (2001).
Lee, J. J. et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin. Cancer Res. 6, 1702–1710 (2000).First comprehensive tool for assessing cancer risk of patients with oral premalignant lesions. It incorporates medical/demographic variables, epidemiological factors, and cellular and molecular biomarkers.
Beenken, S. W. et al. Transforming growth factor-α (TGF-α) expression in dysplastic oral leukoplakia: modulation by 13-cis retinoic acid. Head Neck 21, 566–573 (1999).
Toma, S., Mangiante, P. E., Margarino, G., Nicolo, G. & Palumbo, R. Progressive 13-cis-retinoic acid dosage in the treatment of oral leukoplakia. Eur. J. Cancer B Oral Oncol. 28B, 121–123 (1992).
Hong, W. K. et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N. Engl. J. Med. 315, 1501–1505 (1986).
Shin, D. M. et al. Accumulation of p53 protein and retinoic acid receptor-β in retinoid chemoprevention. Clin. Cancer Res. 3, 875–880 (1997).
Kraemer, K. H., DiGiovanna, J. J., Moshell, A. N., Tarone, R. E. & Peck, G. L. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N. Engl. J. Med. 318, 1633–1637 (1988).
Kraemer, K. H., DiGiovanna, J. J. & Peck, G. L. Chemoprevention of skin cancer in xeroderma pigmentosum. J. Dermatol. 19, 715–718 (1992).
Hong, W. K. et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 323, 795–801 (1990).13- cis retinoic acid treatment reduced the risk for second primary tumours by 20% (2 versus 12 patients) in a cohort of 103 patients who were disease free after primary treatment.
Benner, S. E., Pajak, T. F., Lippman, S. M., Earley, C. & Hong, W. K. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J. Natl Cancer Inst. 86, 140–141 (1994).
Shin, D. M. et al. Combined interferon-α, 13-cis-retinoic acid, and α-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J. Clin. Oncol. 19, 3010–3017 (2001).
Matthay, K. K. et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 341, 1165–1173 (1999).
Lippman, S. M. et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J. Natl Cancer Inst. 93, 605–618 (2001).
Recchia, F. et al. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study. Anticancer Res. 20, 1985–1990 (2000).
Park, T. K. et al. Interferon-α 2α, 13-cis-retinoic acid and radiotherapy for locally advanced carcinoma of the cervix: a pilot study. Eur. J. Gynaecol. Oncol. 19, 35–38 (1998).
Lippman, S. M. et al. 13-cis-retinoic acid plus interferon-α-2α: highly active systemic therapy for squamous cell carcinoma of the cervix. J. Natl Cancer Inst. 84, 241–245 (1992).
Cohen, M. H. et al. Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist 6, 4–11 (2001).
Duvic, M. & Cather, J. C. Emerging new therapies for cutaneous T-cell lymphoma. Dermatol. Clin. 18, 147–156 (2000).
Hurst, R. E. Bexarotene ligand pharmaceuticals. Curr. Opin. Investig. Drugs 1, 514–523 (2000).
Khuri, F. R. et al. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 19, 2626–2637 (2001).
Camerini, T. et al. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. J. Clin. Oncol. 19, 1664–1670 (2001).
Decensi, A. & Costa, A. Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer. Eur. J. Cancer 36, 694–709 (2000).
McPherson, K., Steel, C. M. & Dixon, J. M. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 321, 624–628 (2000).
Torrisi, R. & Decensi, A. Fenretinide and cancer prevention. Curr. Oncol. Rep. 2, 263–270 (2000).
Tradati, N. et al. Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR). Cancer Lett. 76, 109–111 (1994).
Ruidi, C. et al. Chemoprevention of cancer of uterine cervix: a study on chemoprevention of retinamide II from cervical precancerous lesions. J. Cell Biochem. Suppl. 29, 140–143 (1997).
Reynolds, C. P. Differentiating agents in pediatric malignancies: retinoids in neuroblastoma. Curr. Oncol. Rep. 2, 511–518 (2000).
Veronesi, U. & Decensi, A. Retinoids for ovarian cancer prevention: laboratory data set the stage for thoughtful clinical trials. J. Natl Cancer Inst. 93, 486–488 (2001).
Zhang, D., Holmes, W. F., Wu, S., Soprano, D. R. & Soprano, K. J. Retinoids and ovarian cancer. J. Cell Physiol. 185, 1–20 (2000).
Clifford, J. L. et al. Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer. Cancer Epidemiol. Biomarkers Prev. 10, 391–395 (2001).
Thaller, C. et al. Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration. J. Clin. Oncol. 18, 3804–3808 (2000).
Weiss, H. L. et al. Bayesian monitoring of a phase II chemoprevention trial in high-risk cohorts for prostate cancer. Urology 57, 220–223 (2001).
Muto, Y. et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N. Engl. J. Med. 334, 1561–1567 (1996).Polyprenoic acid reduced the risk for second primary hepatocellular carcinomas by 22% (12 versus 22 patients) in a cohort of 89 patients who were free of disease after surgical resection of a primary hepatoma or the percutaneous injection of ethanol.
Muto, Y., Moriwaki, H. & Saito, A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N. Engl. J. Med. 340, 1046–1047 (1999).
DiSilvestro, P. A., DiSilvestro, J. M., Lenhardt, W., Pfahl, M. & Mannel, R. S. Treatment of cervical intraepithelial neoplasia levels 2 and 3 with adapalene, a retinoid-related molecule. J. Lower Genital Tract Dis. 5, 33–37 (2001).
Acknowledgements
Online Tables 1 and 2 are also available from the authors on request. We thank P. Germain for critically reading the manuscript and all our colleagues for discussion and communicating unpublished studies to us, in particular S. Minucci, P. G. Pelicci, A. Zelent, D. Grimwade, P. Chambon, M. Lanotte, C. Chomienne, Y. Shiratori and A. Fanjul. We apologize to all colleagues whose work could only be cited inadequately due to space limitation. L.A. is particularly grateful for support by the Institut National de la Santé et de la Recherche Médicale (INSERM). Our studies mentioned in the text have been supported by funds from the European Community, the AICR, INSERM, the Centre National de la Recherche Scientifique, the Hôpital Universitaire de Strasbourg and Bristol-Myers Squibb.
Author information
Authors and Affiliations
Supplementary information
Supplementary Table 1 Growth-inhibitory and apoptogenic effects of retinoids in preclinical studies.
Supplementary Table 2 Retinoid/rexinoid receptors retinoid/rexinoid responsivity and tumour progression. (PDF 89 kb)
Related links
Glossary
- AP1
-
A transcription factor that is composed of c-JUN, either as a homodimer or as a heterodimer with c-FOS. Both are 'immediate-early genes': expression of these genes is low or undetectable in quiescent cells, but is activated within minutes after extracellular stimulation, such as addition of a growth factor.
- ACUTE PROMYELOCYTIC LEUKAEMIA
-
(APL). A subtype of acute myelocytic leukaemia (AML), also referred to as AML–M3 in the French–American–British (FAB) classification; it is caused by chromosomal translocations involving RARα; the most common translocation (t(15;17)) generates a PML–RARα fusion protein that causes a block in differentiation of promyelocytes.
- TERATOGEN
-
An agent that is capable of causing malformations in embryos.
- COREPRESSORS (CoRs)
-
Proteins that cooperate with nuclear hormone receptors to repress transcription. CoRs tether histone deacetylase (HDAC)-containing complexes to target gene promoters. The two main nuclear receptor corepressors are NCoR (nuclear receptor corepressor) and SMRT (silencing mediator for retinoid and thyroid hormone receptor).
- CO-ACTIVATORS (CoAs)
-
Proteins that cooperate with nuclear hormone receptors to activate transcription. Two classes are known: the p160 family, which recruits histone acetyltransferases, and the TRAP/DRIP/SMCC complex, which is thought to interact with the basal transcription machinery.
- MORPHOGEN
-
A diffusible substance that carries positional information in the embryo, thereby determining the differentiation pathway that cells detecting this information will undergo.
- CRE–LOX
-
A technology that allows genes to be ablated in a tissue-selective and inducible manner.
- PHORBOL ESTERS
-
Polycyclic esters that are isolated from croton oil. The most common is phorbol myristoyl acetate (PMA, also known as 12,13-tetradecanoyl phorbol acetate or TPA). They are potent co-carcinogens or tumour promoters because they mimic diacylglycerol, thereby irreversibly activating protein kinase C.
- SQUAMOUS- AND SPINOUS-CELL CARCINOMAS
-
Carcinomas that develop from the squamous or spinous layers of the epithelium.
- BASAL-CELL CARCINOMA
-
A common carcinoma that is derived from the basal cells of the epidermis; often a consequence of exposure to sunlight and much more common in those with fair skin; it rarely metastasizes.
- LEIOMYOMA
-
A benign tumour of smooth muscle in which parallel arrays of smooth muscle cells form bundles that are arranged in a whorled pattern. Leiomyoma of the uterus (fibroid) is the most common form.
Rights and permissions
About this article
Cite this article
Altucci, L., Gronemeyer, H. The promise of retinoids to fight against cancer. Nat Rev Cancer 1, 181–193 (2001). https://doi.org/10.1038/35106036
Issue Date:
DOI: https://doi.org/10.1038/35106036
This article is cited by
-
Retinoids and EZH2 inhibitors cooperate to orchestrate anti-oncogenic effects on bladder cancer cells
Cancer Gene Therapy (2024)
-
Human nutritional relevance and suggested nutritional guidelines for vitamin A5/X and provitamin A5/X
Nutrition & Metabolism (2023)
-
Neurospora crassa is a potential source of anti-cancer agents against breast cancer
Breast Cancer (2022)
-
Cellular retinol binding protein-1 inhibits cancer stemness via upregulating WIF1 to suppress Wnt/β-catenin pathway in hepatocellular carcinoma
BMC Cancer (2021)
-
Mitochondrial GRIM-19 deficiency facilitates gastric cancer metastasis through oncogenic ROS-NRF2-HO-1 axis via a NRF2-HO-1 loop
Gastric Cancer (2021)